首页 / 院系成果 / 成果详情页

Association of Serum Level of Growth Differentiation Factor 15 with Liver Cirrhosis and Hepatocellular Carcinoma 期刊论文

编号：

28e5d5dd-5fe7-491a-a621-3b1b11872814
作者：

Liu, Xiuying#^[1,2]Chi, Xiumei(迟秀梅)#^[3]Gong, Qiaoling#^[1,2]Gao, Lei^[1,2];Niu, Yuqiang^[1,2];Chi, Xiaojing^[1,2];Cheng, Min^[1,2];Si, Youhui^[1,2];Wang, Maorong^[4];Zhong, Jin(钟劲)*^[5]Niu, Junqi(牛俊奇)*^[3]Yang, Wei(杨威)*^[1,2]
语种：

英文
期刊：

PLOS ONE ISSN：1932-6203 2015 年 10 卷 5 期 ; MAY 21
收录：
摘要：

Hepatocellular carcinoma (HCC) and liver cirrhosis are associated with high mortality worldwide. Currently, alpha-fetoprotein (AFP) is used as a standard serum marker for the detection of HCC, but its sensitivity and specificity are unsatisfactory, and optimal diagnostic markers for cirrhosis are lacking. We previously reported that growth differentiation factor 15 (GDF15) was significantly induced in HCV-infected hepatocytes. This study aimed to investigate GDF15 expression and its correlation with hepatitis virus-related liver diseases. A total of 412 patients with various liver diseases were studied. Healthy and Mycobacterium tuberculosis-infected subjects were included as controls. Serum and tissue GDF15 levels were measured. Serum GDF15 levels were significantly increased in patients with HCC (6.66 +/- 0.67 ng/mL, p<0.0001) and cirrhosis (6.51 +/- 1.47 ng/mL, p<0.0001) compared with healthy controls (0.31 +/- 0.01 ng/mL), though the GDF15 levels in HBV and HCV carriers were moderately elevated (1.34 +/- 0.19 ng/mL and 2.13 +/- 0.53 ng/mL, respectively). Compared with HBV or HCV carriers, GDF15 had a sensitivity of 63.1% and a specificity of 86.6% at the optimal cut-off point of 2.463 ng/mL in patients with liver cirrhosis or HCC. In HCC patients, the area under the receiver operating curve was 0.84 for GDF15 and 0.76 for AFP, but 0.91 for the combined GDF15 and AFP. Serum GDF15 levels did not significantly differ between the high-AFP and low-AFP groups. GDF15 protein expression in HCC was significantly higher than that in the corresponding adjacent paracarcinomatous tissue and normal liver. Using a combination of GDF15 and AFP will improve the sensitivity and specificity of HCC diagnosis. Further research and the clinical implementation of serum GDF15 measurement as a biomarker for HCC and cirrhosis are recommended.
推荐引用方式
GB/T 7714：

Liu Xiuying,Chi Xiumei,Gong Qiaoling, et al. Association of Serum Level of Growth Differentiation Factor 15 with Liver Cirrhosis and Hepatocellular Carcinoma [J].PLOS ONE,2015,10(5).
APA：

Liu Xiuying,Chi Xiumei,Gong Qiaoling,Gao Lei,&Yang Wei.(2015).Association of Serum Level of Growth Differentiation Factor 15 with Liver Cirrhosis and Hepatocellular Carcinoma .PLOS ONE,10(5).
MLA：

Liu Xiuying, et al. "Association of Serum Level of Growth Differentiation Factor 15 with Liver Cirrhosis and Hepatocellular Carcinoma" .PLOS ONE 10,5(2015).
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：36  下载次数：0

分享到：

浏览次数：36

下载次数：0

打印次数：0